Insider Selling: Penumbra, Inc. (NYSE:PEN) Director Sells 360 Shares of Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 360 shares of the company’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $266.93, for a total value of $96,094.80. Following the completion of the sale, the director now owns 4,692 shares in the company, valued at approximately $1,252,435.56. This represents a 7.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Thomas Wilder also recently made the following trade(s):

• On Monday, March 31st, Thomas Wilder sold 360 shares of Penumbra stock. The shares were sold at an average price of $264.58, for a total value of $95,248.80.

Penumbra Trading Down 4.0 %

Shares of PEN stock traded down $10.87 on Friday, reaching $262.37. 576,790 shares of the stock were exchanged, compared to its average volume of 406,932. The stock has a 50 day moving average price of $274.48 and a 200 day moving average price of $245.21. The stock has a market cap of $10.11 billion, a PE ratio of 771.66, a P/E/G ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a one year low of $148.00 and a one year high of $310.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Penumbra (NYSE:PEN) last released its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. The company had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. Equities research analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on PEN shares. Royal Bank of Canada increased their price objective on Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 19th. Oppenheimer assumed coverage on shares of Penumbra in a research report on Tuesday, December 17th. They set an “outperform” rating and a $275.00 target price for the company. UBS Group boosted their price target on shares of Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Robert W. Baird raised their price objective on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a report on Wednesday, February 19th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a report on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Hedge Funds Weigh In On Penumbra

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Penumbra in the 4th quarter valued at $573,000. State Street Corp increased its holdings in Penumbra by 0.3% in the third quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after purchasing an additional 3,863 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in Penumbra by 10.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after purchasing an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Penumbra by 1.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock valued at $64,493,000 after buying an additional 3,807 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Penumbra by 1.7% during the 3rd quarter. Geode Capital Management LLC now owns 655,572 shares of the company’s stock worth $127,417,000 after buying an additional 11,257 shares during the period. 88.88% of the stock is owned by institutional investors.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.